Press release
published
05 Sep
by Carlson Investments SE
Unlike traditional PCR systems, which require complex laboratory infrastructure and cold-chain logistics, Bioaccure’s patented PCR.smart analyzer integrates sample preparation, DNA isolation, amplification, detection, and interpretation into a single, portable device. The platform delivers lab-quality results in under 90 minutes, making advanced diagnostics accessible across diverse environments.
With applications spanning plant and animal health, food safety, water quality, and veterinary diagnostics, Bioaccure empowers farmers, food producers, distributors, veterinarians, and inspectors to identify pathogens with unmatched speed, sensitivity, and cost efficiency. Current ready-to-use assays include detection of Salmonella spp., Campylobacter spp., Listeria monocytogenes, E. coli, and Fusarium species, with an expanding pipeline tailored to industry needs.
Key Features of Bioaccure
End-to-end workflow from DNA isolation to result interpretation in under 90 minutes
Supports qPCR, PCR, and LAMP assays
No need for cold storage or sample transport
Detects bacteria, viruses, fungi, parasites, and genetic mutations
Designed for non-specialist users with simple, intuitive operation
About Bioaccure
Bioaccure is a molecular diagnostics innovator specializing in real-time PCR platforms for field and industrial use. Its patented PCR.smart system combines portability, accuracy, and speed to deliver lab-quality results in agriculture, veterinary medicine, and food safety applications.
About Carlson Investments SE
Carlson Investments SE, listed on Warsaw’s NewConnect and the German Open Market (Frankfurt, Munich, Stuttgart, Gettex), supports high-growth early-stage tech ventures across healthtech, AI, fintech, and deeptech. Carlson applies a hands-on investment approach and integrates its portfolio companies into a global network of strategic partnerships.
Risk Disclaimer
This announcement • does not constitute investment advice or a solicitation to buy or sell financial instruments • involves risks, including possible loss of capital • does not guarantee future earnings • past performance is not indicative of future results.
WE ARE PUBLICLY LISTED, YOU CAN BUY OUR SHARES ON:
Warsaw Stock Exchange (PLN): CAI, PLHOTB000011
Frankfurt Stock Exchange (EUR): 2HB (FRA), PLHOTB000011
Munich Stock Exchange (EUR): 2HB (MUN), PLHOTB000011
Stuttgart Stock Exchange (EUR): 2HB (STU), PLHOTB000011
GETTEX Exchange (EUR): 2HB (GET), PLHOTB000011
WKN: A0RNWQ
Press Contact:
Management Office
Carlson Investments SE
ir@carlsonvc.com
www.carlsonvc.com
ir@carlsonvc.com
Category : Business, Finance, Employment & Investment
Tags : Venture Capital, Startup, MedTech, Veterinary Medicine, Food Safety
###
All the content in published press releases at Viral Press Releases is written and submitted by the press release author.
Viral Press Releases DO NOT accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in any published press release on viralpressreleases.com
If you have any question regarding some information in a press release, please contact the person listed in 'Media Contacts ' at the bottom of press release page.
Please DO NOT attempt to contact Viral Press Releases. We will be unable to assist you with any information regarding any published press release on Viral Press Releases.
Viral Press Releases disclaims any content contained in any published press release on Viral Press Releases.